Karen H. Antman

Karen H. Antman, MD, is Dean of Boston University School of Medicine and Provost of the Boston University Medical Campus

Dr. Antman developed standards for the treatment of patients receiving chemotherapy including pharmacology, growth factors and mobilization of peripheral blood derived stem cells for blood and marrow transplant.

Her professional affiliations include serving on the Administration Board of the Association of American Medical Colleges Council of Deans, the Journal of the American Medical Association Oversight Committee, the International Editorial Board of Lancet, and on the board of the Educational Commission for Foreign Medical Graduates (ECFMG). She was elected to the Institute of Medicine in 2011.

She has served as an associate editor of the New England Journal of Medicine, and on the Council of the National Institutes of Health’s Fogarty International Center. Her publications number more than 300, and she is the editor of four textbooks: Asbestos-related Malignancies, Sarcomas of bone and soft tissue, High-dose cancer therapy that includes pharmacology, hematopoietins and stem cells (three editions), Molecular Targeting in Oncology).

Dr. Antman's publications also include reviews and editorials on medical policy and the impact of research funding and managed care on American clinical research. She has testified before congressional subcommittees on eight occasions on National Institutes of Health (NIH) appropriations and medical policy. She has lectured to lay audiences and has written articles in Vogue and in Readers Digest on cancer prevention and screening.

Antman KH. Current concepts: Malignant mesothelioma. N Engl J. Med. 303:200-202, 1980.

Antman KH, Livingston DM. Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody. Cell. 19:627-635, 1980.

Antman K, Klegar K, Pomfret E, Osteen R, Amato D, Larsos D, Corson J, Early peritoneal mesothlioma: A treatable malignancy. Lancet. ii:977-982, 1985.

...
Wikipedia